

1 **Mutational alterations in the QRDR regions associated with fluoroquinolone resistance in**
2 ***Pseudomonas aeruginosa* of clinical origin from Savar, Dhaka**

3 Md. Shamsul Arefin^{1¶}, Meftahul Jannat Mitu^{1¶}, Shomaia Yasmin Mitu¹, Azmeri Noorjahan², Mir
4 Mobin¹, Shamsun Nahar¹, Hasnain Anjum^{1,3*}, M. Hasibur Rahman^{1*}

5 ¹Department of Microbiology, Jahangirnagar University, Savar, Dhaka.

6 ²Department of Biotechnology and Genetic Engineering, Jahangirnagar University, Savar, Dhaka

7 ³Department of Microbiology, Primeasia University, Banani, Dhaka.

8

9 * Corresponding Authors

10 Email: anjumabir27@gmail.com (HA); hasiburku@juniv.edu (MHR)

11

12 [¶]MSA and MJM contributed equally to this study.

13

14

15

16

17

18

19

20

21 **Mutational alterations in the QRDR regions associated with fluoroquinolone resistance in**
22 ***Pseudomonas aeruginosa* of clinical origin from Savar, Dhaka**

23 **Abstract**

24 Bacterial DNA gyrase and topoisomerase IV are the major targets of quinolone antibiotic, and mutational
25 alterations in quinolone resistance determining regions (QRDR) serve as major mechanism of resistance in
26 most bacterial species, including *P. aeruginosa*. The present investigation was aimed to study the molecular
27 mechanism of fluoroquinolone resistance among clinical *P. aeruginosa* isolated from Dhaka, including
28 alterations in target sites of the antimicrobial action.

29 Laboratory collection of 53 *P. aeruginosa* were subjected to conventional cultural and biochemical
30 characterization, followed by molecular identification using 16S rDNA sequencing. Susceptibility to
31 ciprofloxacin and levofloxacin was tested by disc diffusion method followed by MIC assay. Resistant
32 isolates were analyzed for mutation in their QRDR regions of *gyrA* and *parC*, and subjected to PCR
33 detection of plasmid mediated quinolone resistance (PMQR) genes *qnrA*, *qnrS* and *qnrB*.

34 Among the isolates, 28% were found to be resistant to both fluoroquinolones tested. All of the
35 fluoroquinolone resistant isolates carried a single mutation in *gyrA* (Thr-83-Ile), while 20% carried a single
36 *parC* mutation (Ser-87-Leu). Higher level of MIC was observed in isolates carrying alterations at both sites.
37 None of the isolates harbored any PMQR genes investigated, suggesting that chromosomal mutations in
38 QRDR regions to be the major contributing factor for quinolone resistance in *P. aeruginosa* under
39 investigation.

40 **Keywords:** *Pseudomonas aeruginosa*, Fluoroquinolone resistance, QRDR, PMQR

41

42 **Introduction:**

43 *Pseudomonas aeruginosa* is a cosmopolitan member of the Pseudomonaceae family commonly associated
44 with opportunistic and nosocomial infections [1]. The recent emergence of multidrug-resistant and
45 extensively-drug resistant strains of *P. aeruginosa* is alarming, indicating diminished options of
46 therapeutically effective antibiotics [2]. The nosocomial pathogen can naturally resist a wide range of
47 antibiotics through lower outer membrane permeability, multidrug efflux pumps and chromosomally
48 encoded enzymes [2-4]. Antibiotics like carbapenems, fluoroquinolones, piperacillin, ceftazidime and
49 aminoglycosides are commonly used for treatment of infection caused by *P. aeruginosa* [5]. However,
50 emerging resistance to these antibiotics has been creating outbreaks of multidrug resistant isolates, which
51 is becoming a major infection-related treatment burden [6]. Resistance to drugs like quinolone in *P.*
52 *aeruginosa* increases difficulties in treating severe infections like sepsis and catheter-associated urinary
53 tract infection (CA-UTI) [7].

54 Fluoroquinolone antibiotics, including ciprofloxacin and levofloxacin, can inhibit DNA Gyrase and
55 Topoisomerase of *P. aeruginosa*, leading to bacteriostatic activity [8]. Resistance to these antibiotics is
56 primarily mediated through mutational alterations in the QRDR motif [9]. In *P. aeruginosa*,
57 fluoroquinolone target includes DNA Gyrase (GyrA and GyrB) and DNA Topoisomerase IV (ParC and
58 ParE) molecular subunits, which are responsible for ATP-dependent cleaving and rebinding double-
59 stranded DNA during replication [10]. Fluoroquinolones can bind to GyrA and/or ParC subunits and inhibit
60 the catalytic effect of the protein, resulting inhibition of bacterial DNA replication [11]. Amino acid
61 substitution in the 67-106 motif of the GyrA subunit of *P. aeruginosa* has been reported as the major
62 mechanism of resistance against the antibiotic, as it leads to a reduced binding affinity between
63 fluoroquinolones and GyrA [12-13]. Evidence suggests that substitution of amino acid residues Thr83 of
64 the QRDR motif in GyrA is essential for the development of quinolone-resistant *P. aeruginosa* [13-15]

65 Additional mutational alteration in the QRDR motif of ParC subunit of DNA topoisomerase IV has also
66 been associated with increased level of quinolone resistance in *P. aeruginosa* [13].

67 Alongside mutational alteration in the QRDR motif of GyrA and ParC, other resistance mechanisms also
68 significantly contribute to reduced quinolone sensitivity in *P. aeruginosa*. This includes overexpression of
69 efflux molecular pumps like MexAB-OprM and MexCD-OprJ through mutational alterations in their
70 regulatory genes *mexR* and *nfxB*, respectively [16], and acquisition of PMQR genes like *qnrA*, *qnrB*, *qnrC*
71 and *qnrS* [17]. Therefore, the aim of the present study was to investigate the DNA sequences of *P.*
72 *aeruginosa* QRDR motifs to understand the association of fluoroquinolone tolerance level and alteration in
73 GyrA and ParC, as well as the prevalence of PMQR variants in clinical *P. aeruginosa* isolates from
74 Bangladesh.

75 **Materials and Methods:**

76 **Bacterial Isolates:**

77 Laboratory collection of 53 clinical *P. aeruginosa* collected from two renowned hospitals in Savar was
78 investigated in this study. Sample types included urine, pus, secondary wound infection swab, burn wounds,
79 catheter swab blood and tracheal aspirate. Reconfirmation of the isolates' identity was conducted using
80 conventional cultural and biochemical characterization following Bargey's Manual of Systemic
81 Bacteriology [18-20]. For further verification of their identity, fourteen representative isolates from
82 different antibiotic resistance pattern were subjected to 16SrDNA sequencing using *fd1* and *rp2* primers
83 (Table 1) and identity of the isolates was confirmed by BLAST analysis of the sequences using an online
84 database (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>).

85 **Screening of fluoroquinolone resistance in clinical *P. aeruginosa*:**

86 Fluoroquinolone susceptibility among the clinical *P. aeruginosa* isolates were determined by disc diffusion
87 assay against Ciprofloxacin and Levofloxacin, followed by minimum inhibitory concentration analysis by
88 agar dilution method. Results were interpreted according to Clinical Laboratory Standard Institute (CLSI)
89 standards [21]. *P. aeruginosa* ATCC 27853 was used as control for this experiment.

90 **Sequence analysis of the QRDRs in GyrA and ParC:**

91 Fluoroquinolone resistant isolates were subjected to analysis of alterations in their GyrA and ParC subunits
92 of DNA Gyrase and Topoisomerase IV, respectively. The amplification of putative QRDR region in *gyrA*
93 and *parC* gene was carried out using primer sequence and conditions obtained from a previous study [22].
94 Purified PCR-amplified products were sequenced by the dideoxy chain-termination method [46]. Sequence
95 alignment and amino acid alterations were analyzed by Bioedit Sequence Alignment Editor (version
96 7.0.5.3). The sequences were compared with associated *P. aeruginosa* PAO1 loci from NCBI GenBank as
97 reference.

98 **PCR Amplification of Plasmid Mediated Quinolone Resistance** 99 **(PMQR) genes:**

100 The presence of three different variants of *qnr* genes namely *qnrA*, *qnrB* and *qnrS* were investigated in all
101 isolates exhibiting phenotypic resistance against fluoroquinolone antibiotics. The primers and annealing
102 temperatures are enlisted in Table 1.

103

104

105

106

107 **Table 1. Primers used in this study**

| Gene | Primer Sequence (5' to 3') | Use | Annealing Temperature | Amplicon Size/ Nucleotide Position | Reference |
|-------------|-------------------------------|--|-----------------------|---------------------------------------|-----------|
| <i>gyrA</i> | GAC GGC CTG AAG CCG GTG CAC | Amplification and sequencing of GyrA subunit of Topoisomerase II | 65°C | 115-135 | [22] |
| | GCC CAC GGC GAT ACC GCT GGA | | | 531-511 | |
| <i>parC</i> | CGA GCA GGC CTA TCT GAA CTA T | Amplification and sequencing of parC subunit of Topoisomerase IV | 55°C | 63-84 | |
| | GAA GGA CTT GGG ATC GTC CCG A | | | 366-344 | |
| <i>qnrA</i> | AGA GGA TTT CTC ACG CCA GG | Amplification of QnrA | 54°C | 580bp | [23] |
| | TGC CAG GCA CAG ATC TTG AC | | | | |
| <i>qnrB</i> | CCT GAG CGG CAC TGA ATT TAT | Amplification of QnrB | 60°C | 390bp | [24] |
| | GTT TGC TGC TCG CCA GTC GA | | | | |
| <i>qnrS</i> | GCA AGT TCA TTG AAC AGG GT | Amplification of QnrS | 54°C | 428bp | [23] |
| | TCT AAA CCG TCG AGT TCG GCG | | | | |
| fd1 | TCT AAA CCG TCG AGT TCG GCG | Amplification and sequencing of 16S rDNA | 42°C | 1500bp | [25] |
| rp2 | ACG GCT ACC TTG TTA CGA CTT | | | | |

108

109 **Results:**

110 **Fluoroquinolone resistance in *P. aeruginosa*:**

111 All 53 isolates of *P. aeruginosa* were subjected to fluoroquinolone susceptibility test against ciprofloxacin

112 and levofloxacin by disk-diffusion method followed by minimum inhibitory concentration (MIC) assay.

113 Among them, 15 (28%) were found to be resistant to both ciprofloxacin and levofloxacin, and all resistant
114 isolates exhibited a high tolerance level to the fluoroquinolones tested (≥ 16 to ≥ 128 $\mu\text{g/ml}$).

115 Sequence analysis of QRDR regions:

116 The amino acid alterations in GyrA and ParC QRDR regions of 15 fluoroquinolone resistant *P. aeruginosa*
117 was analyzed by sequencing and comparing with the corresponding sequences of *P. aeruginosa* PAO1.
118 According to the pattern of amino acid alteration, the isolates were categorized into two distinct groups.
119 Group I consisted of isolates with a single mutation at Thr-83-Ile in *gyrA*, while Group II contained one
120 mutation at Thr-83-Ile in *gyrA* and one mutation at Ser-87-Leu in *parC* (Table 2). Among the 15 isolates,
121 all carried a single mutation (Thr-83-Ile) in *gyrA*. Single mutation in *parC* (Ser-87-Leu) was also found in
122 3 of 15 isolates (19%). No additional mutations were observed in the QRDR regions. Sequence data of *gyrA*
123 and *parC* from a representative isolate carrying mutations at both sites (PWS10) have been submitted to
124 the GenBank databases under accession numbers PP501828 (*gyrA*) and PP526740 (*parC*).

125 **Table 2. Amino acid alterations in *gyrA* and *parC* in fluoroquinolone resistant *P. aeruginosa* isolates**

| Groups | No. of Isolates | Alterations in QRDR | |
|--------|-----------------|-------------------------|-------------------------|
| | | <i>gyrA</i> at position | <i>parC</i> at position |
| | | 83 | 87 |
| PAO1 | | Thr (ACC) | Ser (TCG) |
| I | 12 | Ile (ATC) | - |
| II | 3 | Ile (ATC) | Leu (TTG) |

126

127 QRDR mutations in both *gyrA* and *parC* subunit reveals high level of tolerance against both ciprofloxacin
 128 and levofloxacin (MIC value ≥ 128 $\mu\text{g/ml}$) (Table 3). Isolates with a single *gyrA* mutation had
 129 fluoroquinolone MIC ranges from 16 to 64 $\mu\text{g/ml}$.

130 **Table 3. Association of mutations in QRDR region and tolerance level against fluoroquinolones**

| Group | No. of Isolates | Fluoroquinolone antibiotics | No. of isolates with corresponding MIC ($\mu\text{g/ml}$) value | | | | | | | | |
|--|-----------------|-----------------------------|---|---|---|---|---|----|----|----|-----|
| | | | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 |
| I; | 12 | Ciprofloxacin | | | | | | 5 | 5 | 2 | |
| Single alteration in <i>gyrA</i> (83) | | Levofloxacin | | | | | | 1 | 6 | 5 | |
| II; | 3 | Ciprofloxacin | | | | | | | | | 3 |
| Alterations in <i>gyrA</i> (83) and <i>parC</i> (87) | | Levofloxacin | | | | | | | | | 3 |

131

132 **Occurrence of PMQR genes:**

133 PCR detection of three PMQR variants (*qnrA*, *qnrB* and *qnrS*) revealed that none of the 15 fluoroquinolone
 134 resistant isolates carried the PMQR genes (Fig 1).

135 **Fig 1. PCR based detection of PMQR variants.** Variants *qnr* gene sequences were PCR amplified using
 136 specific primers (Table 1). PCR products were electrophoresed through 1% agarose gels, stained with
 137 ethidium bromide, and visualized with UV light. The 100 bp DNA ladder indicates the size of PCR
 138 products. Lane 2, 6 and 10 represent variant-specific positive controls, and lane 3, 7 and 11 represent
 139 negative controls. No isolates were positive in *qnrA*, *qnrB* and *qnrS* specific PCR.

140 **Discussion:**

141 *Pseudomonas aeruginosa* can employ multiple mechanisms to resist therapeutically important antibiotics
142 like the fluoroquinolones. Beside decreased level of antibiotic accumulation using lower outer membrane
143 permeability and active molecular efflux pumps, alteration of QRDR motifs within topoisomerase II (GyrA
144 and GyrB subunits) and topoisomerase IV (ParC and ParE subunits) has been considered to be the principal
145 mechanism of fluoroquinolone resistance [26-29]. Several important pathogens, including *E. coli*,
146 *Staphylococcus aureus*, *Streptococcus pneumoniae* and *Neisseria gonorrhoeae* has been found to have *gyrA*
147 as their primary target of mutation alone or in combination with *parC* gene [14, 30-32]. Additional mutation
148 of *mexR*, *nfxC* or *nfxB* genes are also found to cause limited sensitivity to quinolones [13, 33-34].

149 In *Pseudomonas aeruginosa*, alteration at position 83 in *gyrA* is most commonly associated with high level
150 of resistance [12, 35]. Mutation from Threonine to a hydrophobic amino acid at this position tends to
151 generally confer more resistance than other similar alterations at position 87, as observed in several reports
152 [12-14]. The present study observed that all fluoroquinolone resistant isolates carried a single mutation at
153 position 83, where threonine (Thr) was replaced with Isoleucine (Ile) (Table 2). The result is in accordance
154 with previous studies, as it is reported as the most common site of mutation at the QRDR region [13-14,
155 37-38]. Additional novel mutations in *gyrA* have also been reported, including Asp-87-Asn, Asp-87-Gly
156 and Gln-106-Leu, which often occurs along with alterations at position 83 and associated with high MIC
157 level [15, 38-39]. However, none of the isolates in this study had such alterations at position 87 and 106.
158 Although Thr-83-Ile mutation can result resistance to second-generation quinolones like ciprofloxacin and
159 levofloxacin as observed in this study (Table 3), its effect has been seen to be limited on more recent
160 generation of quinolones like sitafloxacin and clinafloxacin [34].

161 Substitution of Leu for Ser-87 in *parC* subunit was observed in three isolates. This substitution is closely
162 associated with fluoroquinolone resistance, and has been reported as a second step mutation in isolates
163 already having a single alteration of *gyrA* in *P. aeruginosa* [13, 15]. This supports the present data, as the

164 isolates with alteration Ser-87-Leu in *parC* also carried alteration Thr-83-Ile in *gyrA*. These isolates had a
165 elevated level of both ciprofloxacin and levofloxacin MIC (≥ 128 $\mu\text{g/ml}$). Additional mechanism of
166 resistance like overexpression of efflux pump MexAB-OprM by mutational alteration of *mexR* could also
167 contribute to fluoroquinolone resistance in *P. aeruginosa* [34]. However, no phenotypic evidence of efflux
168 pump overexpression was observed in efflux inhibitor induced MIC depression assay in this study (data not
169 shown), so analysis of mutation in *mexR* has not been conducted.

170 Although variants of PMQR genes like *qnrA*, *qnrB*, *qnrC*, *qnrD* and *qnrS* are not frequently found in *P.*
171 *aeruginosa* [40], several recent studies have reported the increasing number of occurrences of PMQR genes
172 in clinical *P. aeruginosa* [41-42]. But none of the quinolone resistant isolates from this study were seen to
173 be harboring any of the three variants of *qnr* genes tested. Quinolone resistance through acquisition of
174 PMQR genes is a mechanism commonly observed among the members of the *Enterobacteriaceae* family
175 [43], and was first discovered by Martinez *et al.* that it could be transmitted to *P. aeruginosa* in vitro as
176 well [44]. This is a major concern as acquisition of such resistance elements can further diminish the
177 antimicrobial activity of fluoroquinolones [45].

178 **Conclusion:**

179 Culmination of data from this study suggests mutational alteration at QRDR regions, especially GyrA is
180 the most significant mechanism of resistance to fluoroquinolones. Although other mechanisms like
181 acquisition of PMQR and overexpression of efflux pumps contribute to resistance, the results indicate that
182 mutational alteration alone can lead to the development of resistance against second generation
183 fluoroquinolones like ciprofloxacin and levofloxacin. Broad spectrum antibiotics like fluoroquinolones are
184 one of the safest therapeutic options to treat infections caused by *P. aeruginosa*. However, the ever-
185 increasing resistance to the antibiotics is a major concern. Due to the bacteria's incredible capacity in
186 acquiring and resisting various antibiotics, it is essential to raise awareness to implement antibiotic
187 stewardship.

188 **Data Availability**

189 Sequence data of *gyrA* and *parC* from a representative isolate is available at the GenBank databases under
190 Accession numbers PP501828 (*gyrA*) and PP526740 (*parC*).

191 **Ethics statement**

192 This study was approved by the Ethics and Research Review Committee of the Jahangirnagar University
193 Faculty of Biological Sciences [Ref No: BBEC, JU/M 2020 (1)4]. Written informed consent was obtained
194 from patients for sample collection, and their personal identities along with other information were
195 anonymized.

196 **Acknowledgments:**

197 The authors would like to thank the laboratory personnel of Enam Medical College Hospital and
198 Gonoshasthaya Medical College Hospital, Dhaka, Bangladesh, for their support in the collection of the
199 clinical samples.

200 **Conflicts of Interest:**

201 The authors declare that they have no conflict of interest.

202 **Reference:**


- 203 1. Tümmler B. Emerging therapies against infections with *Pseudomonas aeruginosa*. *F1000Research*. 2019;8..
- 204 2. Anjum H, Arefin MS, Jahan N, Oishee MJ, Nahar S, Islam S, et al. Roles of intrinsic and acquired resistance determinants
205 in multidrug-resistant clinical *Pseudomonas aeruginosa* in Bangladesh. *Bangladesh Journal of Medical Science*. 2023 Jul 1;22(3).
- 206 3. Hancock RE. Resistance mechanisms in *Pseudomonas aeruginosa* and other nonfermentative gram-negative bacteria.
207 *Clinical Infectious Diseases*. 1998 Aug 1;27(Supplement_1):S93-9.

- 208 4. Livermore DM. Multiple mechanisms of antimicrobial resistance in *Pseudomonas aeruginosa*: our worst nightmare?
209 *Clinical infectious diseases*. 2002 Mar 1;34(5):634-40.
- 210 5. Pachori, P., Gothwal, R., & Gandhi, P. (2019). Emergence of antibiotic resistance *Pseudomonas aeruginosa* in intensive
211 care unit; a critical review. *Genes & diseases*, 6(2), 109-119.
- 212 6. Raman, G., Avendano, E. E., Chan, J., Merchant, S., & Puzniak, L. (2018). Risk factors for hospitalized patients with
213 resistant or multidrug-resistant *Pseudomonas aeruginosa* infections: a systematic review and meta-analysis. *Antimicrobial
214 Resistance & Infection Control*, 7, 1-14.
- 215 7. Hsu DI, Okamoto MP, Murthy R, Wong-Beringer A. Fluoroquinolone-resistant *Pseudomonas aeruginosa*: risk factors
216 for acquisition and impact on outcomes. *Journal of Antimicrobial Chemotherapy*. 2005 Apr 1;55(4):535-41.
- 217 8. Correia S, Poeta P, Hébraud M, Capelo JL, Igrejas G. Mechanisms of quinolone action and resistance: where do we
218 stand?. *Journal of medical microbiology*. 2017 May;66(5):551-9.
- 219 9. Le Thomas I, Couetdic G, Clermont O, Brahimi N, Plesiat P, Bingen E. In vivo selection of a target/efflux double mutant
220 of *Pseudomonas aeruginosa* by ciprofloxacin therapy. *Journal of Antimicrobial Chemotherapy*. 2001 Oct 1;48(4):553-5.
- 221 10. Bush NG, Evans-Roberts K, Maxwell A. DNA topoisomerases. *EcoSal Plus*. 2015 Dec 31;6(2):10-128.
- 222 11. Rehman A, Patrick WM, Lamont IL. Mechanisms of ciprofloxacin resistance in *Pseudomonas aeruginosa*: new
223 approaches to an old problem. *Journal of Medical Microbiology*. 2019 Jan;68(1):1-0.
- 224 12. Madurga S, Sánchez-Céspedes J, Belda I, Vila J, Giralt E. Mechanism of binding of fluoroquinolones to the quinolone
225 resistance-determining region of DNA gyrase: Towards an understanding of the molecular basis of quinolone resistance.
226 *Chembiochem*. 2008 Sep 1;9(13):2081-6.
- 227 13. Lee JK, Lee YS, Park YK, Kim BS. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and
228 ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of *Pseudomonas aeruginosa*. *International journal of
229 antimicrobial agents*. 2005 Apr 1;25(4):290-5.
- 230 14. Ostrer L, Khodursky RF, Johnson JR, Hiasa H, Khodursky A. Analysis of mutational patterns in quinolone resistance-
231 determining regions of GyrA and ParC of clinical isolates. *International journal of antimicrobial agents*. 2019 Mar 1;53(3):318-24.
- 232 15. Akasaka T, Tanaka M, Yamaguchi A, Sato K. Type II topoisomerase mutations in fluoroquinolone-resistant clinical
233 strains of *Pseudomonas aeruginosa* isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
234 *Antimicrobial agents and chemotherapy*. 2001 Aug 1;45(8):2263-8.

- 235 16. Jalal S, Ciofu O, Høiby N, Gotoh N, Wretling B. Molecular mechanisms of fluoroquinolone resistance in *Pseudomonas*
236 *aeruginosa* isolates from cystic fibrosis patients. *Antimicrobial agents and chemotherapy*. 2000 Mar 1;44(3):710-2.
- 237 17. Cayci YT, Coban AY, Gunaydin M. Investigation of plasmid-mediated quinolone resistance in *Pseudomonas aeruginosa*
238 clinical isolates. *Indian journal of medical microbiology*. 2014 Jul 1;32(3):285-9.
- 239 18. Brenner DJ, Boone DR, Garrity GM, Goodfellow M, Krieg NR, Rainey FA, et al. The Proteobacteria: Part C: The Alpha-,
240 Beta-, Delta-, and Epsilonproteobacteria. Athens, GA, USA: Bergey's Manual Trust; 2005.
- 241 19. Gilardi GL. Characterization of *Pseudomonas* species isolated from clinical specimens. *Applied Microbiology*. 1971
242 Mar;21(3):414-9.
- 243 20. Cappuccino JG, Sherman N. *Microbiology: a laboratory manual*. Pearson Higher Ed; 2013 Feb 20.
- 244 21. CLSI. *Performance Standards for Antimicrobial Susceptibility Testing*. 31st ed.
- 245 22. Lee JK, Lee YS, Park YK, Kim BS. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and
246 ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of *Pseudomonas aeruginosa*. *International journal of*
247 *antimicrobial agents*. 2005 Apr 1;25(4):290-5.
- 248 23. Cattoir V, Poirel L, Rotimi V, Soussy CJ, Nordmann P. Multiplex PCR for detection of plasmid-mediated quinolone
249 resistance *qnr* genes in ESBL-producing enterobacterial isolates. *Journal of antimicrobial chemotherapy*. 2007 Aug 1;60(2):394-7.
- 250 24. Wu JJ, Ko WC, Tsai SH, Yan JJ. Prevalence of plasmid-mediated quinolone resistance determinants *QnrA*, *QnrB*, and
251 *QnrS* among clinical isolates of *Enterobacter cloacae* in a Taiwanese hospital. *Antimicrobial agents and chemotherapy*. 2007
252 Apr;51(4):1223-7.
- 253 25. Weisburg WG, Barns SM, Pelletier DA, Lane DJ. 16S ribosomal DNA amplification for phylogenetic study. *Journal of*
254 *bacteriology*. 1991 Jan;173(2):697-703.
- 255 26. Zhao L, Wang S, Li X, He X, Jian L. Development of in vitro resistance to fluoroquinolones in *Pseudomonas aeruginosa*.
256 *Antimicrobial resistance & infection control*. 2020 Dec;9:1-8.
- 257 27. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. *Microbiology and molecular biology reviews*.
258 1997 Sep;61(3):377-92.
- 259 28. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection.
260 *Journal of Antimicrobial Chemotherapy*. 2003 May 1;51(5):1109-17.

- 261 29. Komp Lindgren P, Karlsson AS, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in *Escherichia*
262 *coli* isolates from patients with urinary tract infections. *Antimicrobial agents and chemotherapy*. 2003 Oct;47(10):3222-32.
- 263 30. Al-Kobaisi MF. Jawetz, Melnick & Adelberg's Medical Microbiology 24th Edition. Sultan Qaboos University Medical
264 Journal. 2007 Dec 1;7(3):273-5.
- 265 31. Bhatnagar K, Wong A. The mutational landscape of quinolone resistance in *Escherichia coli*. *PLoS One*. 2019 Nov
266 5;14(11):e0224650.
- 267 32. de Korne-Elenbaas J, Pol A, Vet J, Dierdorp M, van Dam AP, Bruisten SM. Simultaneous detection of *Neisseria*
268 *gonorrhoeae* and fluoroquinolone resistance mutations to enable rapid prescription of oral antibiotics. *Sexually transmitted diseases*.
269 2020 Apr 1;47(4):238-42.
- 270 33. Ma Z, Xu C, Zhang X, Pan X, Bai F, Cheng Z, Wu W, Jin Y. A MexR mutation which confers aztreonam resistance to
271 *Pseudomonas aeruginosa*. *Frontiers in Microbiology*. 2021 Jun 24;12:659808.
- 272 34. Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates
273 of *Pseudomonas aeruginosa*. *International journal of antimicrobial agents*. 2003 May 1;21(5):409-13.
- 274 35. Sada M, Kimura H, Nagasawa N, Akagawa M, Okayama K, Shirai T, et al. Molecular evolution of the *Pseudomonas*
275 *aeruginosa* DNA gyrase *gyrA* gene. *Microorganisms*. 2022 Aug 17;10(8):1660.
- 276 36. JALAL S, WRETLIND B. Mechanisms of quinolone resistance in clinical strains of *Pseudomonas aeruginosa*. *Microbial*
277 *Drug Resistance*. 1998;4(4):257-61.
- 278 37. Park Y, Oh J, Park S, Sum S, Song W, Chae J, Park H. Antimicrobial resistance and novel mutations detected in the *gyrA*
279 and *parC* genes of *Pseudomonas aeruginosa* strains isolated from companion dogs. *BMC veterinary research*. 2020 Dec;16:1-8.
- 280 38. Oh H, Stenhoff J, Jalal S, Wretlind B. Role of efflux pumps and mutations in genes for topoisomerases II and IV in
281 fluoroquinolone-resistant *Pseudomonas aeruginosa* strains. *Microbial Drug Resistance*. 2003 Dec 1;9(4):323-8.
- 282 39. Nakano M, Deguchi T, Kawamura T, Yasuda M, Kimura M, Okano Y, et al. Mutations in the *gyrA* and *parC* genes in
283 fluoroquinolone-resistant clinical isolates of *Pseudomonas aeruginosa*. *Antimicrobial agents and chemotherapy*. 1997
284 Oct;41(10):2289-91.
- 285 40. Ude J, Tripathi V, Buyck JM, Söderholm S, Cunrath O, Fanous J, et al. Outer membrane permeability: Antimicrobials
286 and diverse nutrients bypass porins in *Pseudomonas aeruginosa*. *Proceedings of the National Academy of Sciences*. 2021 Aug
287 3;118(31):e2107644118.

- 288 41. Saki M, Farajzadeh Sheikh A, Seyed-Mohammadi S, Asareh Zadegan Dezfuli A, Shahin M, Tabasi M, et al. Occurrence
289 of plasmid-mediated quinolone resistance genes in *Pseudomonas aeruginosa* strains isolated from clinical specimens in southwest
290 Iran: a multicentral study. *Scientific Reports*. 2022 Feb 10;12(1):2296.
- 291 42. Nabilou M, Babaeekhou L, Ghane M. Fluoroquinolone resistance contributing mechanisms and genotypes of
292 ciprofloxacin-unsusceptible *Pseudomonas aeruginosa* strains in Iran: emergence of isolates carrying *qnr/aac (6)-Ib* genes.
293 *International Microbiology*. 2021:1-1.
- 294 43. Azargun R, Gholizadeh P, Sadeghi V, Hosainzadegan H, Tarhriz V, Memar MY, et al. Molecular mechanisms associated
295 with quinolone resistance in Enterobacteriaceae: review and update. *Transactions of the Royal Society of Tropical Medicine and*
296 *Hygiene*. 2020 Oct;114(10):770-81.
- 297 44. Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. *The Lancet*. 1998 Mar
298 14;351(9105):797-9.
- 299 45. Rodríguez-Martínez JM, Machuca J, Cano ME, Calvo J, Martínez-Martínez L, Pascual A. Plasmid-mediated quinolone
300 resistance: two decades on. *Drug Resistance Updates*. 2016 Nov 1;29:13-29.
- 301 46. Walker SE, Lorsch J. Sanger dideoxy sequencing of DNA. In *Methods in enzymology* 2013 Jan 1 (Vol. 529, pp. 171-
302 184). Academic Press.



Figure